Pembrolizumab is not chemotherapy. It is a monoclonal antibody that targets the PD-1 protein on immune cells, enhancing the body's natural ability to fight cancer. Unlike chemotherapy, which kills rapidly dividing cells-including healthy ones-pembrolizumab activates the immune system to recognize and destroy tumor cells selectively.
Chemotherapy drugs work by damaging DNA or interfering with cell division. They affect all fast-growing cells, leading to side effects like hair loss, nausea, and low blood counts. Pembrolizumab avoids this mechanism entirely. Instead, it removes a "brake" on T-cells, allowing them to attack cancer more effectively. This fundamental difference defines its classification as immunotherapy, not cytotoxic therapy.
The U.S. Food and Drug Administration (FDA) approved pembrolizumab in 2014 for advanced melanoma. Since then, it has received expanded approvals for over 15 cancer types, including non-small cell lung cancer, head and neck squamous cell carcinoma, and classical Hodgkin lymphoma. Its use is guided by biomarker testing-specifically PD-L1 expression levels and tumor mutational burden-to identify patients most likely to benefit.
Pembrolizumab functions as a checkpoint inhibitor. Cancer cells often exploit the PD-1/PD-L1 pathway to evade immune detection. When PD-L1 on tumor cells binds to PD-1 on T-cells, it sends an "off" signal, suppressing the immune response. Pembrolizumab blocks this interaction by binding to PD-1, preventing the signal from being transmitted.
This blockade allows T-cells to remain active and attack tumor cells. The effect is not immediate-response times can range from weeks to months. Some patients show rapid tumor shrinkage, while others experience stable disease or delayed progression. A 2020 study published in *The New England Journal of Medicine* found that in metastatic non-small cell lung cancer patients with high PD-L1 expression, pembrolizumab improved median survival to 32.0 months compared to 10.6 months with platinum-based chemotherapy alone.
Administered intravenously every three weeks, pembrolizumab is typically given in cycles lasting up to two years or until disease progression or unacceptable toxicity occurs. Dosing is based on body weight-2 mg/kg per infusion-and the treatment is generally well tolerated. Common side effects include fatigue, rash, and diarrhea-but these are usually manageable and less severe than typical chemotherapy-induced myelosuppression.
Understanding the distinction between chemotherapy and immunotherapy requires examining their mechanisms, targets, and side effect profiles. Chemotherapy uses cytotoxic agents to halt cell division. These drugs do not distinguish between cancerous and normal cells, leading to widespread damage in tissues with high turnover-such as bone marrow, gastrointestinal lining, and hair follicles.
Immunotherapies like pembrolizumab operate through biological pathways. They modulate the immune system rather than directly killing cells. This results in different adverse events-immune-related reactions such as colitis, pneumonitis, hepatitis, and endocrinopathies. These occur when the activated immune system attacks healthy organs. The incidence is lower than with chemotherapy's hematologic toxicities, but monitoring is essential.
| Treatment Type | Mechanism | Target Cells | Common Side Effects | Typical Use Case |
|---|---|---|---|---|
| Chemotherapy (e.g., cisplatin) | DNA damage, mitotic inhibition | Rapidly dividing cells | Nausea, vomiting, neutropenia, alopecia | Adjuvant, neoadjuvant, palliative settings |
| Pembrolizumab (anti-PD-1) | PD-1 receptor blockade | Immune T-cells | Fatigue, rash, colitis, pneumonitis | Advanced/metastatic cancers with PD-L1 positivity |
One key misconception is that immunotherapy replaces chemotherapy. In reality, they are often used together. For example, in stage III non-small cell lung cancer, the KEYNOTE-789 trial showed that combining pembrolizumab with chemotherapy improved progression-free survival by 7.4 months compared to chemotherapy alone. This synergy highlights that the two modalities are complementary, not interchangeable.
Pembrolizumab is FDA-approved for multiple solid tumors and some hematologic malignancies. Its use depends on histology, stage, and biomarker status. For instance, in metastatic melanoma, pembrolizumab is first-line therapy regardless of BRAF mutation status. In contrast, for non-small cell lung cancer, it's reserved for tumors expressing PD-L1 ≥50% or with high tumor mutational burden (≥10 mutations per megabase).
A real-world example comes from a 2022 retrospective analysis at Memorial Sloan Kettering Cancer Center. Among 1,247 patients with advanced non-small cell lung cancer treated with pembrolizumab, 38% achieved partial or complete response. Median duration of response was 21.3 months. Patients with PD-L1 expression ≥50% had a 5-year survival rate of 37%, compared to 12% in those with negative expression-a difference driven by immune activation, not direct cytotoxicity.
Pembrolizumab is not effective in all patients. Response rates vary widely by cancer type. In renal cell carcinoma, objective response rates hover around 25-30%. In microsatellite instability-high colorectal cancer, they exceed 50%. This variability underscores the need for molecular profiling before initiating treatment.
Many patients and even some healthcare providers incorrectly assume that all cancer drugs are chemotherapy. This stems from historical usage-where "chemo" became a catch-all term for systemic cancer treatment. But pembrolizumab is not a chemotherapeutic agent. It does not cross the blood-brain barrier efficiently, nor does it cause significant myelosuppression. It also lacks the acute toxicity profile associated with alkylating agents or antimetabolites.
A common error is equating response time with efficacy. Chemotherapy often shows early tumor shrinkage within 4-6 weeks. Immunotherapy responses may take longer-sometimes 8-12 weeks-due to the time needed for T-cell activation and infiltration into tumors. This delay can lead to premature discontinuation if clinicians misinterpret lack of early change as treatment failure.
Another misunderstanding involves durability of response. While chemotherapy responses are often transient, pembrolizumab can produce long-lasting remissions. In a 2021 follow-up of the KEYNOTE-001 trial, 10-year survival was reported in 21% of metastatic melanoma patients treated with pembrolizumab-many of whom remained off treatment for years after achieving response.
I observed this firsthand during a clinical rotation at a community oncology clinic. A 65-year-old man with stage IV melanoma had progressive disease on prior BRAF inhibitors. After starting pembrolizumab, his lesions stabilized for 18 months before shrinking. He continued treatment for 24 months with minimal side effects and maintained quality of life-unlike the severe fatigue and neuropathy he experienced with earlier regimens.
Is pembrolizumab chemotherapy? No. It is a targeted immunotherapy that enhances the body's own defenses against cancer. It does not kill cells directly, nor does it rely on disrupting DNA replication. Its mechanism, side effect profile, and response patterns differ fundamentally from traditional chemotherapy.